AUG 5·SEC EDGARLow
Dhaliwal Harpreet S. sold $935K of PCVX
Dhaliwal Harpreet S. (Chief Technical Ops Officer) sold 17,000 shares of Vaxcyte, Inc. (PCVX) at $55.00 ($0.94M total) on 2026-08-05 under a Rule 10b5-1 trading plan.
StockNASDAQ · US · USDHealthcare · Biotechnology
$PCVX
Vaxcyte, Inc.
Price · $PCVXvia TradingView
AI sentiment · 7d1 articles
- Bullish
- 1
- Neutral
- 0
- Bearish
- 0
Top stories · $PCVXMore →
AUG 5·SEC EDGAR 8-K
Vaxcyte, Inc. (PCVX): Results of Operations and Financial Condition
Vaxcyte, Inc. (PCVX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 pcvx-20260805xexx991.htm EX-99.1 Document Exhibit 99.1 Vaxcyte Reports Second Quarter 2026 Financial Results and Provides Business Update Topline Safety, Tolerability and Immunogenicity Data from VAX-31 Adult Phase 3 OPUS-1 Trial Expected in Fourth Quarter of 2026; OPUS
AUG 5·SEC EDGAR
GUGGENHIME ANDREW sold $539K of PCVX
GUGGENHIME ANDREW (PRESIDENT AND CFO) sold 10,000 shares of Vaxcyte, Inc. (PCVX) at an average of $53.89 ($53.76–$54.18, $0.54M total) across 2 trades on 2026-08-03 under a Rule 10b5-1 trading plan.
PCVX sentiment & insider activity
Over the past 7 days, alphai's AI scored 1 news story mentioning PCVX (Vaxcyte, Inc.). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent PCVX coverage spans insider activity, corporate actions and earnings.
In the last 30 days, PCVX insiders filed 11 SEC Form 4 transactions — no purchases and 11 sales ($2.6M). The most active reporter was PICKERING GRANT, CHIEF EXECUTIVE OFFICER, with 6 filings. 100% of activity was filed under pre-arranged Rule 10b5-1 plans.
What's driving PCVX
This is a routine, pre-arranged insider sale disclosure, not a fundamental company update.
Near-term catalyst is OPUS-1 topline in Q4 2026, with additional Phase 3 readouts in H1 2027 supporting a potential BLA submission and U.S. launch path.
Routine 10b5-1 insider selling by the CFO, with no accompanying operational or guidance change disclosed.
Insider selling under a pre-arranged 10b5-1 plan is typically low-signal for fundamentals, but it can still affect near-term sentiment and positioning.
Board composition update is unlikely to change near-term fundamentals, but it can affect governance and committee oversight.
alphai scores every news story that mentions PCVX with an AI model for sentiment and relevance, and aggregates insider trades from Vaxcyte, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
News on $PCVX
Score
Dhaliwal Harpreet S. sold $935K of PCVX
Dhaliwal Harpreet S. (Chief Technical Ops Officer) sold 17,000 shares of Vaxcyte, Inc. (PCVX) at $55.00 ($0.94M total) on 2026-08-05 under a Rule 10b5-1 trading plan.
1 min readVaxcyte, Inc. (PCVX): Results of Operations and Financial Condition
Vaxcyte, Inc. (PCVX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 pcvx-20260805xexx991.htm EX-99.1 Document Exhibit 99.1 Vaxcyte Reports Second Quarter 2026 Financial Results and Provides Business Update Topline Safety, Tolerability and Immunogenicity Data from VAX-31 Adult Phase 3 OPUS-1 Trial Expected in Fourth Quarter of 2026; OPUS
6 min readGUGGENHIME ANDREW sold $539K of PCVX
GUGGENHIME ANDREW (PRESIDENT AND CFO) sold 10,000 shares of Vaxcyte, Inc. (PCVX) at an average of $53.89 ($53.76–$54.18, $0.54M total) across 2 trades on 2026-08-03 under a Rule 10b5-1 trading plan.
2 min readPICKERING GRANT sold $901K of PCVX
PICKERING GRANT (CHIEF EXECUTIVE OFFICER) sold 16,198 shares of Vaxcyte, Inc. (PCVX) at an average of $55.63 ($55.52–$55.93, $0.90M total) across 2 trades on 2026-07-27 under a Rule 10b5-1 trading plan.
2 min readVaxcyte, Inc. (PCVX): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Vaxcyte, Inc. (PCVX) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. pcvx-20260713 0001649094 FALSE 825 Industrial Road Suite 300 San Carlos California 0001649094 2026-07-13 2026-07-13 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 _____________________________________________ FORM 8-K _____________________________________
2 min readTop U.S. Healthcare Stocks to Watch, According to Mizuho By Investing.com
Mizuho, via Investing.com, highlighted seven U.S. healthcare stocks for growth, citing clinical catalysts and operational updates. Price targets and ratings include EYPT $36, PCVX $163, ERAS $26, ARQT $35, LNTH $115, EHC $134, and SOLV $100. Key items include EYPT Phase 3 data in Aug 2026, PCVX Phase 3 in 4Q 2026, and LNTH PDUFA mid-Aug 2026.
4 min readGUGGENHIME ANDREW sold $573K of PCVX
GUGGENHIME ANDREW (PRESIDENT AND CFO) sold 10,000 shares of Vaxcyte, Inc. (PCVX) at an average of $57.28 ($57.16–$57.76, $0.57M total) across 2 trades on 2026-07-06 under a Rule 10b5-1 trading plan.
1 min readVaxcyte Inc (PCVX) Is A Hidden Multibagger Stock To Buy Now
Vaxcyte (PCVX) updated investors on an early-stage trial of its VAX-A1 vaccine for Group A strep, testing three dose levels vs placebo in healthy young adults to assess safety, tolerability, and immunogenicity. Mizuho Securities reiterated a Buy rating and set a $163 price target, citing about 180% upside.
3 min readPICKERING GRANT sold $1.2M of PCVX
PICKERING GRANT (CHIEF EXECUTIVE OFFICER) sold 22,237 shares of Vaxcyte, Inc. (PCVX) at an average of $55.21 ($54.28–$56.12, $1.23M total) across 3 trades on 2026-06-26 under a Rule 10b5-1 trading plan.
2 min readVaxcyte, Inc. (PCVX): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Vaxcyte, Inc. (PCVX) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. pcvx-20260617 0001649094 FALSE 825 Industrial Road Suite 300 San Carlos California 0001649094 2026-06-17 2026-06-17 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 _____________________________________________ FORM 8-K _____________________________________
3 min read